The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Abstract
The amyloid cascade hypothesis, which posits that the deposition of the amyloid-β peptide in the brain is a central event in Alzheimer's disease pathology, has dominated research for the past twenty years. Several therapeutics that were purported to reduce amyloid-β production or aggregation have failed in Phase III clinical testing, and many others are in various stages of development. Therefore, it is timely to review the science underpinning the amyloid cascade hypothesis, consider what type of clinical trials will constitute a valid test of this hypothesis and explore whether amyloid-β-directed therapeutics will provide the medicines that are urgently needed by society for treating this devastating disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pathogenetic studies have shown that Aβ peptide accumulation in the brain is an early and central event, 2”
From Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer’s Disease (2022) · cites this paper as [2]
In the citing paper
“One possible resolution is that amyloid pathology acts only as a trigger in sporadic AD (Karran et al., 2011); i.e., Aβ accumulation is necessary but insufficient to cause full-blown disease.”
From The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques (2019) · cites this paper as Karran et al., 2011
In the citing paper
“since it is known that the Aβ plaques act as a driver of AD pathology63 and the accumulation Aβ plaques in the brain initiates a complex multicellular neurodegenerative process.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [63]
In the citing paper
“The amyloid cascade hypothesis, which dominated the field for over three decades, proposed that the abnormal accumulation of Aβ initiates a downstream cascade leading to tau hyperphosphorylation, synaptic dysfunction, and neuronal death [6, 7].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [7]
In the citing paper
“a possible cause of clinical failure could be the difficulty of inhibiting these proteinases without causing side effects resulting from non-targeted proteolytic inhibition on their many physiological substrates”
From Emerging Alternative Proteinases in APP Metabolism and Alzheimer’s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP (2019) · cites this paper as Karran et al., 2011
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 1×
“The apolipoprotein E ( APOE ) gene represents the major genetic risk factor for A”
BackgroundAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“The discovery that AD could be inherited in an autosomal dominant fashio”
Background
Research works printed but not linked: 2
- Burns, A. & Ilife, S. Dementia. BMJ 338, 405–409 (2009).
- Alzheimer, A. About a peculiar disease of the cerebral cortex. [in German] Centralblatt für Nervenheilkunde Psychiatrie 30, 177–179 (1907).
Cited by
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
“Unfortunately, many clinical trials have been inadequately designed to robustly test the amyloid hypothesis, such that negative trial results cannot be necessarily interpreted as a rejection of the amyloid hypothesis (Karran and Hardy, 2014; Karran et al., 2011).”
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
The amyloid state and its association with protein misfolding diseases.
Knowles, T. P. J., Vendruscolo, M., & Dobson, C. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3810 · Cited by 2,382
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., Sealock, J., Karlsson, I. K., Hägg, S., Athanasiu, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0311-9 · Cited by 2,277
Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185
“The mutations are divided in three categories: mutations at the β-secretase cleavage site (N-term), at the γ-secretase cleavage site (C-term) and in the mid-domain amyloid-β region [29].”
BackgroundNelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
“In sum, clinical trials have not provided definitive answers as to the direct role of A A Ps or tangles in the cognitive impairment associated with AD pathologic diagnosis (80, 81).”
BackgroundThe Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
Self-citationThe toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Self-citationAlzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758
Neuroinflammation and M2 Microglia: The Good, the Bad, and the Inflamed
Cherry, J. D., Olschowka, J. A., & O’Banion, M. K. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-98 · Cited by 1,748
“These observations have led to the inflammatory cascade hypothesis of Alzheimer’s disease, which states that Aβ deposition induces neuroinflammation, which in turn generates more Aβ, resulting in a vicious cycle [120].”
BackgroundBiomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
Network abnormalities and interneuron dysfunction in Alzheimer disease
Palop, J. J., & Mucke, L. (2016) · Nature reviews. Neuroscience · doi:10.1038/nrn.2016.141 · Cited by 1,022
Sala Frigerio, C., Wolfs, L., Fattorelli, N., Thrupp, N., Voytyuk, I., Schmidt, I., Mancuso, R., Chen, W.-T., Woodbury, M. E., Srivastava, G., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.099 · Cited by 926
“One possible resolution is that amyloid pathology acts only as a trigger in sporadic AD (Karran et al., 2011); i.”
BackgroundSelf-citationSpatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease
Chen, W.-T., Lu, A., Craessaerts, K., Pavie, B., Sala Frigerio, C., Corthout, N., Qian, X., Laláková, J., Kühnemund, M., Voytyuk, I., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.038 · Cited by 949
Dominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
Webster, S. J., Bachstetter, A. D., Nelson, P. T., Schmitt, F. A., & Van Eldik, L. J. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00088 · Cited by 755
“The data also support the “Amyloid Cascade Hypothesis”(Karran et al., 2011), a deceptively complex hypothesis which posits that beta-amyloid/plaque pathology kin-dles widespread tau/NFT pathology, with the tau/NFT pathology constituting the more direct cause of the cell loss and synapse elimination underlying clinical…”
ResultThe amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742
Self-citationHistory and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
“However, when some mutations, such as the Lys670Asn/ Met671Leu (Swedish) and Ala673Val mutations near the BACE1 cleavage site, are present,(77,78) APP is prone to hydrolysis by the β pathway, resulting in an excessive accumulation of insoluble Aβ and eventually the development of AD.(79,80) However, the Ala673Thr muta…”
BackgroundThe β-Secretase BACE1 in Alzheimer’s Disease
Hampel, H., Vassar, R., De Strooper, B., Hardy, J., Willem, M., Singh, N., Zhou, J., Yan, R., Vanmechelen, E., De Vos, A., et al. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.02.001 · Cited by 694
Alzheimer’s disease prevention: from risk factors to early intervention
Crous-Bou, M., Minguillón, C., Gramunt, N., & Molinuevo, J. L. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0297-z · Cited by 687
“Cerebral Aβ deposition is considered a necessary, but not sufficient, step on the path towards AD development [44].”
BackgroundBioinorganic Chemistry of Alzheimer’s Disease
Kepp, K. P. (2012) · Chemical Reviews · doi:10.1021/cr300009x · Cited by 672
Cholinesterase inhibitors as Alzheimer's therapeutics (Review)
Sharma, K. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10374 · Cited by 602
“The progressive synthesis and aggregation of β -amyloid (a β ), a proteolytic fragment derived from amyloid precursor protein (aPP), are additional critical factors involved in ad pathogenesis (7).”
BackgroundAlzheimer’s disease hypothesis and related therapies
Du, X., Wang, X., & Geng, M. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0107-y · Cited by 607
“Actually, the strategy of targeting only a single functional subregion of Aβ may partly account for these failures [27, 28].”
BackgroundHansson, O., Edelmayer, R. M., Boxer, A. L., Carrillo, M. C., Mielke, M. M., Rabinovici, G. D., Salloway, S., Sperling, R., Zetterberg, H., & Teunissen, C. E. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12756 · Cited by 607
“(6) Additional data are needed for use of BBMs in primary care.”
MethodSavelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Amyloid-β-independent regulators of tau pathology in Alzheimer disease
van der Kant, R., Goldstein, L. S. B., & Ossenkoppele, R. (2020) · Nature reviews. Neuroscience · doi:10.1038/s41583-019-0240-3 · Cited by 580
Verghese, P. B., Castellano, J. M., Garai, K., Wang, Y., Jiang, H., Shah, A., Bu, G., Frieden, C., & Holtzman, D. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220484110 · Cited by 556
“amyloid-(1-40): The role of salt bridges.”
A review on coumarins as acetylcholinesterase inhibitors for Alzheimer’s disease
Anand, P., Singh, B., & Singh, N. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.12.042 · Cited by 527
Metabolism and functions of copper in brain
Scheiber, I. F., Mercer, J. F. B., & Dringen, R. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.01.002 · Cited by 506
Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer’s disease
Kaur, D., Sharma, V., & Deshmukh, R. (2019) · Inflammopharmacology · doi:10.1007/s10787-019-00580-x · Cited by 484
Alzheimer disease therapy—moving from amyloid-β to tau
Giacobini, E., & Gold, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.223 · Cited by 471
Alzheimer’s disease and its treatment by different approaches: A review
Srivastava, S., Ahmad, R., & Khare, S. K. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113320 · Cited by 467
TREM2, microglia, and neurodegenerative diseases
Yeh, F. L., Hansen, D. V., & Sheng, M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.008 · Cited by 440
“[581_TD$DIFF]Just as targeting b-secretase to reduce Ab production is a possible therapeutic approach for AD [150], inhibiting proteolytic shedding to increase surface TREM2 on microglia may also be a viable strategy.”
BackgroundDominguez, L. J., Veronese, N., Vernuccio, L., Catanese, G., Inzerillo, F., Salemi, G., & Barbagallo, M. (2021) · Nutrients · doi:10.3390/nu13114080 · Cited by 433
“Amyloid-beta accumulation further induces neuroinflammation, which produces more amyloid-beta aggregation, leading to a vicious cycle of propagating injury [444].”
BackgroundImaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
Villemagne, V. L., Doré, V., Burnham, S. C., Masters, C. L., & Rowe, C. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.9 · Cited by 441
Gowrishankar, S., Yuan, P., Wu, Y., Schrag, M., Paradise, S., Grutzendler, J., De Camilli, P., & Ferguson, S. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510329112 · Cited by 406
“J Neuropathol Exp Neurol 64(2):113–122.”
The amyloid cascade hypothesis: are we poised for success or failure?
Karran, E., & De Strooper, B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13632 · Cited by 402
“This situation is concordant with amyloid Ab either triggering a disease process, or surmounting some threshold before the disease is provoked (reviewed in Karran et al. 2011).”
BackgroundSelf-citationHou, K., Zhao, J., Wang, H., Li, B., Li, K., Shi, X., Wan, K., Ai, J., Lv, J., Wang, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18525-2 · Cited by 373
Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery
Patching, S. G. (2017) · Molecular Neurobiology · doi:10.1007/s12035-015-9672-6 · Cited by 361
Metallostasis in Alzheimer's disease
Ayton, S., Lei, P., & Bush, A. I. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.10.558 · Cited by 352
“has been effective in preventing cognitive decline in patients with AD [37-40].”
BackgroundAlzheimer's disease: From immunotherapy to immunoprevention
Jucker, M., & Walker, L. C. (2023) · Cell · doi:10.1016/j.cell.2023.08.021 · Cited by 353
Calcium signaling and molecular mechanisms underlying neurodegenerative diseases
Pchitskaya, E., Popugaeva, E., & Bezprozvanny, I. (2018) · Cell Calcium · doi:10.1016/j.ceca.2017.06.008 · Cited by 349
“However, so far these agents did not show benefit in AD clinical trials (Cummings et al., 2014; Karran and Hardy, 2014; Karran et al., 2011).”
BackgroundNew Insights Into the Pathogenesis of Alzheimer's Disease
Fan, L., Mao, C., Hu, X., Zhang, S., Yang, Z., Hu, Z., Sun, H., Fan, Y., Dong, Y., Yang, J., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2019.01312 · Cited by 344
Simon, M. J., & Iliff, J. J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.014 · Cited by 342
“According to the dominant ‘Amyloid Cascade Hypothesis of AD’, increasing levels of interstitial amyloid β species impair synaptic function, promoting tau aggregation and NFT formation and resulting in neurodegeneration [80, 81].”
BackgroundMi, Y., Qi, G., Vitali, F., Shang, Y., Raikes, A. C., Wang, T., Jin, Y., Brinton, R. D., Gu, H., & Yin, F. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00756-4 · Cited by 343
Karthikeyan, A., Joseph, A., & Nair, B. G. (2022) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-021-00290-4 · Cited by 336
“Many hypotheses illustrate these mechanisms, the most accepted of which is the amyloid cascade hypothesis that proposes the abnormal amyloid is processed by beta and gamma secretases and as the main event of AD [107] (Fig.”
BackgroundAmyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease
Baranello, R., Bharani, K., Padmaraju, V., Chopra, N., Lahiri, D., Greig, N., Pappolla, M., & Sambamurti, K. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666141218140953 · Cited by 331
“Whether A accumulation or hyperphosphorylated tau contribute to the disease pathogenesis or are merely bystander markers of the disorder, remains a matter of intense debate [8-12].”
Backgroundβ-Amyloid: the key peptide in the pathogenesis of Alzheimer’s disease
Sun, X., Chen, W.-D., & Wang, Y.-D. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00221 · Cited by 323
“Therefore, Aβ is predicted to be the most potentially efficient target of the drug therapies (Karran et al., 2011).”
BackgroundChronic stress and glucocorticoids: From neuronal plasticity to neurodegeneration
Vyas, S., Rodrigues, A. J., Silva, J. M., Tronche, F., Almeida, O. F. X., Sousa, N., & Sotiropoulos, I. (2016) · Neural Plasticity · doi:10.1155/2016/6391686 · Cited by 297
Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease
Osborn, L. M., Kamphuis, W., Wadman, W. J., & Hol, E. M. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.001 · Cited by 312
“It is generally believed that oligomers of Ab initiate subtle functional changes and both the aggregation state and deposition of Ab set processes in motion that ultimately lead to neuronal malfunction (Karran et al., 2011; Walsh and Selkoe, 2004).”
BackgroundDrugs in Clinical Trials for Alzheimer's Disease: The Major Trends
Bachurin, S. O., Bovina, E. V., & Ustyugov, A. A. (2017) · Medicinal Research Reviews · doi:10.1002/med.21434 · Cited by 304
Shou, Y., Huang, Y., Zhu, X., Liu, C., Hu, Y., & Wang, H. (2019) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2019.02.086 · Cited by 303
Drug repositioning for Alzheimer's disease
Corbett, A., Pickett, J., Burns, A., Corcoran, J., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 301
Molecular mechanisms underlying protective role of quercetin in attenuating Alzheimer's disease
Zaplatic, E., Bule, M., Shah, S. Z. A., Uddin, M. S., & Niaz, K. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.055 · Cited by 293
Interrogating Amyloid Aggregates using Fluorescent Probes
Aliyan, A., Cook, N. P., & Martí, A. A. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00404 · Cited by 290
Aquaporin-4 Water Channel in the Brain and Its Implication for Health and Disease
Mader, S., & Brimberg, L. (2019) · Cells · doi:10.3390/cells8020090 · Cited by 293
“Accumulation of beta-amyloid is a hallmark of AD and can begin years before disease onset [95].”
BackgroundZempel, H., Luedtke, J., Kumar, Y., Biernat, J., Dawson, H., Mandelkow, E., & Mandelkow, E. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.207 · Cited by 283
“In familial AD, genetic evidence points to a master role of A b aggregation, leading to downstream events including Tau hyperphosphorylation and aggregation (Haass and Selkoe, 2007; Karran et al , 2011).”
The amyloid cascade hypothesis: an updated critical review
Kepp, K. P., Robakis, N. K., Høilund-Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023) · Brain · doi:10.1093/brain/awad159 · Cited by 284
Mouse models of Alzheimer’s disease
Esquerda-Canals, G., Montoliu-Gaya, L., Güell-Bosch, J., & Villegas, S. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170045 · Cited by 288
“PP processing and, consequently, on AD development [42].”
VDAC1, mitochondrial dysfunction, and Alzheimer’s disease
Shoshan-Barmatz, V., Nahon-Crystal, E., Shteinfer-Kuzmine, A., & Gupta, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.010 · Cited by 286
Evaluation of optical coherence tomography angiographic findings in Alzheimer’s type dementia
Bulut, M., Kurtuluş, F., Gözkaya, O., Erol, M. K., Cengiz, A., Akıdan, M., & Yaman, A. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2017-310476 · Cited by 276
Lessons from a failed γ-secretase Alzheimer trial
De Strooper, B. (2014) · Cell · doi:10.1016/j.cell.2014.10.016 · Cited by 277
Karran, E., & Hardy, J. (2014) · Annals of Neurology · doi:10.1002/ana.24188 · Cited by 275
“The same purified preparations were also shown to inhibit Ab-mediated toxicity in fetal rat primary hippocampal cells, but the interpretation of direct Ab-mediated toxicity assays is challenging.(9) Other workers also demonstrated an antiaggregatory effect of affinitypurified anti-Ab antibodies on Ab-induced toxicity,…”
BackgroundSelf-citationNeuronal hyperactivity--A key defect in Alzheimer’s disease?
Busche, M. A., & Konnerth, A. (2015) · BioEssays · doi:10.1002/bies.201500004 · Cited by 266
“In agreement with the ‘amyloid cascade hypothesis’ of AD [17, 18, 26], a recent whole-genome sequencing study has found a rare mutation in the APP gene that lowers amyloid-ß production, slows age-dependent cognitive decline and may protect against AD [27].”
ResultVillain, N., Chételat, G., Grassiot, B., Bourgeat, P., Jones, G., Ellis, K. A., Ames, D., Martins, R. N., Eustache, F., Salvado, O., et al. (2012) · Brain · doi:10.1093/brain/aws125 · Cited by 255
“(Karran et al., 2011; Sperling et al., 2011b).”
Current evidence on the effect of dietary polyphenols intake on chronic diseases
Costa, C., Tsatsakis, A., Mamoulakis, C., Teodoro, M., Briguglio, G., Caruso, E., Tsoukalas, D., Margina, D., Dardiotis, E., Kouretas, D., et al. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.10.023 · Cited by 258
“The key components of neurodegeneration in AD are the extracellular neuritic plaques composed by accumulation of abnormally misfolded Aβ peptide, the intracellular neurofibrillary tangles comprised of the microtubuleassociated protein tau and the inflammatory processes (Karran et al., 2011).”
BackgroundKim, K., Kim, M.-J., Kim, D. W., Kim, S. Y., Park, S., & Park, C. B. (2020) · Nature Communications · doi:10.1038/s41467-019-13901-z · Cited by 255
Intestinal microbial dysbiosis aggravates the progression of Alzheimer’s disease in Drosophila
Wu, S.-C., Cao, Z.-S., Chang, K.-M., & Juang, J.-L. (2017) · Nature Communications · doi:10.1038/s41467-017-00040-6 · Cited by 254
Microglial Aβ Receptors in Alzheimer’s Disease
Yu, Y., & Ye, R. D. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-014-0101-6 · Cited by 247
Rajasekhar, K., Chakrabarti, M., & Govindaraju, T. (2015) · Chemical Communications · doi:10.1039/c5cc05264e · Cited by 241
Drug repositioning: Progress and challenges in drug discovery for various diseases
Hua, Y., Dai, X., Xu, Y., Xing, G., Liu, H., Lu, T., Chen, Y., & Zhang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114239 · Cited by 232
“drug substrates remains controversial [14].”
Alzheimer’s Disease: From Firing Instability to Homeostasis Network Collapse
Frere, S., & Slutsky, I. (2018) · Neuron · doi:10.1016/j.neuron.2017.11.028 · Cited by 237
Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update
Cenini, G., & Voos, W. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00902 · Cited by 257
Avrahami, L., Farfara, D., Shaham-Kol, M., Vassar, R., Frenkel, D., & Eldar-Finkelman, H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.409250 · Cited by 231
“Progressive accumulation of A peptides enhances fibrillogenic assembly and formation of A load burdens exerting toxic and disruptive effects on neurons, synaptic plasticity, and cognitive functions (1, 4, 5).”
BackgroundThe Supramolecular Chemistry of β-Sheets
Cheng, P.-N., Pham, J. D., & Nowick, J. S. (2013) · Journal of the American Chemical Society · doi:10.1021/ja3088407 · Cited by 228
Goyal, D., Shuaib, S., Mann, S., & Goyal, B. (2017) · ACS Combinatorial Science · doi:10.1021/acscombsci.6b00116 · Cited by 227
The PI3K/Akt signaling axis in Alzheimer’s disease: a valuable target to stimulate or suppress?
Razani, E., Pourbagheri-Sigaroodi, A., Safaroghli-Azar, A., Zoghi, A., Shanaki-Bavarsad, M., & Bashash, D. (2021) · Cell Stress and Chaperones · doi:10.1007/s12192-021-01231-3 · Cited by 227
“In addition to their neurotoxicity, they provoke astrocytes and microglia cells to release pro-inflammatory cytokines, a process that results in abnormal protein-folding activities, mitochondrial dysfunction, and neuronal cell death (Karran et al. 2011).”
BackgroundChoy, R. W.-Y., Cheng, Z., & Schekman, R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208635109 · Cited by 222
Rasmussen, J., Mahler, J., Beschorner, N., Kaeser, S. A., Häsler, L. M., Baumann, F., Nyström, S., Portelius, E., Blennow, K., Lashley, T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1713215114 · Cited by 227
“The AD brains analyzed in the present study were all from patients with end-stage disease, at which point amyloid, per se, may no longer be the primary driver of the disease (46).”
BackgroundDeveloping Therapeutic Antibodies for Neurodegenerative Disease
Yu, Y. J., & Watts, R. J. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0187-4 · Cited by 227
Treatment of neurodegenerative disorders through the blood–brain barrier using nanocarriers
Poovaiah, N., Davoudi, Z., Peng, H., Schlichtmann, B., Mallapragada, S., Narasimhan, B., & Wang, Q. (2018) · Nanoscale · doi:10.1039/c8nr04073g · Cited by 225
Habchi, J., Chia, S., Limbocker, R., Mannini, B., Ahn, M., Perni, M., Hansson, O., Arosio, P., Kumita, J. R., Challa, P. K., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615613114 · Cited by 223
The Aging Eye: Common Degenerative Mechanisms Between the Alzheimer's Brain and Retinal Disease
Sivak, J. M. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-10827 · Cited by 220
Zilberter, Y., & Zilberter, M. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24064 · Cited by 214
“, 1999), the amyloid hypothesis (Hardy, 2009; Karran et al., 2011), the tau hypothesis (Arendt et al.”
BackgroundMullane, K., & Williams, M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 213
“With seven amyloid-target compounds now having failed in late stage clinical trials, many in the AD research community have questioned whether the amyloid hypothesis has indeed been invalidated [15,19,130] with one biotech analyst enthusiastically”
BackgroundFunctional roles and networks of non-coding RNAs in the pathogenesis of neurodegenerative diseases
Wu, Y.-Y., & Kuo, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00636-z · Cited by 213
Ager, R. R., Davis, J. L., Agazaryan, A., Benavente, F., Poon, W. W., LaFerla, F. M., & Blurton‐Jones, M. (2015) · Hippocampus · doi:10.1002/hipo.22405 · Cited by 212
“However, thus far, such therapies have provided little to no clinical improvements in human trials, despite evidence of reduced A β load (Karran et al., 2011).”
InfluentialZhang, W., Xu, C., Sun, J., Shen, H.-M., Wang, J., & Yang, C. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.008 · Cited by 205
Bourgade, K., Garneau, H., Giroux, G., Le Page, A. Y., Bocti, C., Dupuis, G., Frost, E. H., & Fülöp, T. (2015) · Biogerontology · doi:10.1007/s10522-014-9538-8 · Cited by 208
“The hallmark of AD, in addition to neuronal loss, is the presence of cortical senile plaques and neurofibrillary tangles in the brain of affected patients (Karran et al. 2011; Seeman and Seeman 2011).”
Xu, Z., Jia, S., Wang, W., Yuan, Z., Jan Ravoo, B., & Guo, D.-S. (2019) · Nature Chemistry · doi:10.1038/s41557-018-0164-y · Cited by 204
Molecular links between Alzheimer’s disease and diabetes mellitus
Yang, Y., & Song, W. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.07.009 · Cited by 201
Long, J. M., Ray, B., & Lahiri, D. K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.366336 · Cited by 198
“Alzheimer disease (AD),(2) the most common form of dementia (1), is thought to arise in part from excess accumulation of the amyloid- peptide (A ) (2, 3).”
BackgroundAmyloid-β and Tau at the Crossroads of Alzheimer’s Disease
Gallardo, G., & Holtzman, D. M. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-32-9358-8_16 · Cited by 198
Mitochondrial dysfunction in Alzheimer’s disease
D’Alessandro, M. C. B., Kanaan, S., Geller, M., Praticò, D., & Daher, J. P. L. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102713 · Cited by 192
“The amyloid cascade theory suggests that AD pathology begins with the deposition of A β peptides in the brain, leading to the formation of amyloid plaques (Karran et al., 2011).”
Getting to the Heart of Alzheimer Disease
Tublin, J. M., Adelstein, J. M., del Monte, F., Combs, C. K., & Wold, L. E. (2019) · Circulation Research · doi:10.1161/circresaha.118.313563 · Cited by 188
“The amyloid cascade hypothesis articulates that the pathology behind AD is driven by the deposition of the Aβ peptide in the brain.(17) However, supporters of the vascular hypothesis propose that AD is a vascular disorder, in which the pathology is induced via cerebral microvascular abnormalities.”
Ramanan, V. K., Risacher, S. L., Nho, K., Kim, S., Swaminathan, S., Shen, L., Foroud, T. M., Hakonarson, H., Huentelman, M. J., Aisen, P. S., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.19 · Cited by 200
The Cholinergic System, the Adrenergic System and the Neuropathology of Alzheimer’s Disease
Bekdash, R. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031273 · Cited by 197
Cherry, J. D., Liu, B., Frost, J. L., Lemere, C. A., Williams, J. P., Olschowka, J. A., & O’Banion, M. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0053275 · Cited by 198
“One of the key players in neuroinflammation and one of the two major histopathological hallmarks of the disease is accumulation of amyloid beta (Ab) into extracellular, dense fibril plaques [11].”
Background
Metadata
- Authors
- Karran, E., Mercken, M., & Strooper, B. D.
- Affiliations
- Janssen (Belgium) (BE)
- Vlaams Instituut voor Biotechnologie (BE)
- Corresponding author
- Karran, Eric
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-08-19
- Volume
- 10
- Issue
- 9
- Pages
- 698-712
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2079749054
- Cited by
- 2,188
- References
- 157
- Citations by year
- 2026: 74 · 2025: 115 · 2024: 130 · 2023: 139 · 2022: 141 · 2021: 158 · 2020: 174 · 2019: 191 · 2018: 174 · 2017: 163 · 2016: 171 · 2015: 160 · 2014: 151 · 2013: 130 · 2012: 107
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- amyloid hypothesis, Alzheimer's disease, amyloid-beta, amyloid-beta aggregation, amyloid-beta production, clinical trial design, phase III trial failure, drug development
- MeSH terms
- Alzheimer Disease, Animals, Brain Chemistry, Humans, Research Design, Amyloid beta-Peptides, Treatment Failure, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Age of Onset, Disease Progression, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.